0000950170-24-001295.txt : 20240103
0000950170-24-001295.hdr.sgml : 20240103
20240103183023
ACCESSION NUMBER: 0000950170-24-001295
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231231
FILED AS OF DATE: 20240103
DATE AS OF CHANGE: 20240103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Prout Samantha
CENTRAL INDEX KEY: 0001743122
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33497
FILM NUMBER: 24508859
MAIL ADDRESS:
STREET 1: C/O AMICUS THERAPEUTICS, INC.
STREET 2: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER NAME:
FORMER CONFORMED NAME: Prout Samantha Whiteman
DATE OF NAME CHANGE: 20180607
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001178879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 200422823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: (215) 921-7600
MAIL ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
FORMER COMPANY:
FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC
DATE OF NAME CHANGE: 20020729
4
1
ownership.xml
4
X0508
4
2023-12-31
0001178879
AMICUS THERAPEUTICS, INC.
FOLD
0001743122
Prout Samantha
47 HULFISH STREET
PRINCETON
NJ
08542
false
true
false
false
Chief Accounting Officer
false
Common Stock
2023-12-31
4
F
false
23356
14.19
D
98556
D
Common Stock
2024-01-02
4
A
false
25252
0.0
A
123808
D
Common Stock
2024-01-02
4
F
false
1313
14.24
D
122495
D
Stock Options (right to buy)
14.24
2024-01-02
4
A
false
43592
0
A
2034-01-02
Common Stock
43592
43592
D
Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 2, 2025 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.
/s/ Christian Formica, Attorney-in-Fact
2024-12-03